"The company has received final approval from the United States Food & Drug Administration (USFDA) to manufacture and market Olopatadine Hydrochloride Ophthalmic Solution USP in the strength of 0.1 percent," Aurobindo Pharma said in a regulatory filing today.

The product is generic version of Alcon Laboratories Inc's Patanol ophthalmic solution/drops in the same strength, it added.

The company currently has a total of 225 abbreviated new drug application (ANDA) approvals (197 final approvals including 10 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA, it added.

The stock was today trading at Rs 845.50 in the afternoon trade on BSE, up 1.05 percent from its previous close.

Latest News  from Business News Desk